Eltanexor (KPT-8602) is a newly developed synthetic second-generation XPO1 inhibitor (Figure 1A) and less toxic than analogs, and is currently in phase I/II clinical trials for multiple myeloma (Cornell et al., 2016). Here, XPO1 is linked to plasma cell myeloma.